Research programme: glutaminyl cyclase inhibitors - Probiodrug

Drug Profile

Research programme: glutaminyl cyclase inhibitors - Probiodrug

Alternative Names: PQ 1565

Latest Information Update: 30 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Probiodrug
  • Class Antidementias; Neuroprotectants; Small molecules
  • Mechanism of Action Glutaminyl-peptide cyclotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 28 Nov 2012 Probiodrug and Evotec AG enter a collaborative agreement for the development of glutaminyl cyclase inhibitors for Alzheimer's disease
  • 23 Jul 2012 Interim pharmacodynamics data from a preclinical study in Alzheimer's disease presented at the 41st Annual Meeting of the Society for Neuroscience (SFN-2011)
  • 01 Apr 2011 Preclinical development is ongoing in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top